On May 14, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reported that multiple abstracts from the Company’s tafasitamab program have been accepted for oral and poster presentations at the upcoming 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Meeting, May 29 – May 31, 2020 and at the virtual 25th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) (EHA25 Virtual), June 11-14, 2020 (Press release, MorphoSys, MAY 14, 2020, View Source [SID1234558035]). Tafasitamab is MorphoSys’ investigational anti-CD19 antibody, currently under priority review by the FDA in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to provide a number of important updates on tafasitamab in this new virtual setting," commented Dr. Malte Peters, Chief Research and Development Officer of MorphoSys. "The data we and our partners will present highlight our progress towards making novel therapies available to eligible patients in need as soon as possible."

MorphoSys will meet registered ASCO (Free ASCO Whitepaper)20 Virtual and EHA (Free EHA Whitepaper)25 Virtual attendees at its virtual booths accessible through the conference websites.

Key abstracts accepted for presentation at ASCO (Free ASCO Whitepaper)20 Virtual and EHA (Free EHA Whitepaper)25 Virtual include:

ASCO20 Virtual

E-Poster Presentation

RE-MIND STUDY: A PROPENSITY SCORE-BASED 1:1 MATCHED COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VERSUS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Abstract/Poster No.: 8020/353
Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Presentation Time: Friday, May 29, 2020, 8:00 AM EDT

EHA25 Virtual

Oral Presentation

RE-MIND STUDY: COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Abstract No.: S238
Session: 19. Aggressive Non-Hodgkin lymphoma – Clinical
Presentation Time: Friday, June 12, 8:30 CEST

E-Poster Presentations:

LONG-TERM OUTCOMES FROM THE PHASE II L-MIND STUDY OF TAFASITAMAB (MOR208) PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Abstract No.: EP1201
Session: 19. Aggressive Non-Hodgkin lymphoma – Clinical
Presentation Time: Friday, June 12, 8:30 CEST

EXPRESSION OF CD19 ANTIGEN ON CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AFTER TAFASITAMAB (ANTI-CD19) TREATMENT: PHASE I TRIAL DATA

Abstract No.: EP671
Session: 05. Chronic lymphocytic leukemia and related disorders – Biology & Translational Research
Presentation Time: Friday, June 12, 8:30 CEST

COMBINATION OF TAFASITAMAB (MOR208) AND LENALIDOMIDE ENHANCES TUMOR CELL DEATH OF B-CELL LYMPHOMA IN VITRO
Abstract No.: EP1343
Session: 20. Lymphoma Biology & Translational Research
Presentation Time: Friday, June 12, 8:30 CEST

Please refer to the ASCO (Free ASCO Whitepaper)20 Virtual (View Source) and EHA (Free EHA Whitepaper)25 Virtual (View Source) online programs for full session details and data presentation listings.

About tafasitamab
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. In January 2020, MorphoSys and Incyte Corporation entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. If approved in the U.S., MorphoSys and Incyte will co-commercialize tafasitamab; Incyte will have exclusive commercialization rights outside the U.S. Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials, including L-MIND and Re-MIND. Additionally, tafasitamab is being evaluated as part of the ongoing Phase 3 study B-MIND study assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. Tafasitamab is also currently being investigated in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.